Literature DB >> 11836289

Macroprolactinemia revisited: a study on 106 patients.

Sophie Vallette-Kasic1, Isabelle Morange-Ramos, Adel Selim, Ginette Gunz, Sophie Morange, Alain Enjalbert, Pierre-Marie Martin, Philippe Jaquet, Thierry Brue.   

Abstract

The predominance of high molecular weight PRL, or macroprolactinemia, has long been known in hyperprolactinemic patients with maintained fertility. Among 1,106 consecutive patients investigated for hyperprolactinemia in our center over a 10-yr period, serum PRL chromatography was performed in 368 cases because of discordant clinical, biological, or neuroradiological findings. We prospectively studied the 106 patients with macroprolactinemia (96 women, 6 men, 4 children) and compared them with the 262 hyperprolactinemic patients with a normal PRL elution pattern. We concluded the following: 1) the incidence of macroprolactinemia in our hyperprolactinemic population was at least 10%; 2) despite preserved fertility with uneventful pregnancies, some of the usual symptoms of hyperprolactinemia were present; 3) mean PRL values were 61 +/- 66 microg/liter (range, 20-663) and exceeded 100 microg/liter in 8.5% of patients; 4) PRL levels usually remained stable over time; 5) on dopaminergic therapy, PRL returned to normal in 21 of 45 treated patients; 6) during follow-up of 7 pregnancies, PRL increased to supraphysiological levels in 5; and 7) pituitary magnetic resonance imaging was normal in 78% of patients or revealed diverse pituitary lesions, including adenomas (n = 5). A diagnostic method for macroprolactinemia should be available to all centers to avoid unnecessary hormonal or radiological investigations and treatments.

Entities:  

Mesh:

Substances:

Year:  2002        PMID: 11836289     DOI: 10.1210/jcem.87.2.8272

Source DB:  PubMed          Journal:  J Clin Endocrinol Metab        ISSN: 0021-972X            Impact factor:   5.958


  31 in total

1.  Prevalence of pituitary adenomas in macroprolactinemic patients may be higher than it is presumed.

Authors:  Gonca Tamer; Ayşegül Telci; Meral Mert; Ayse Kubat Uzum; Ferihan Aral; Refik Tanakol; Sema Yarman; Harika Boztepe; Nese Colak; Faruk Alagöl
Journal:  Endocrine       Date:  2011-09-30       Impact factor: 3.633

Review 2.  Long-term management of prolactinomas--use of long-acting dopamine agonists.

Authors:  David M Cook
Journal:  Rev Endocr Metab Disord       Date:  2005-01       Impact factor: 6.514

3.  Prevalence and reproductive manifestations of macroprolactinemia.

Authors:  Amanpreet Kaur Kalsi; Ashutosh Halder; Manish Jain; P K Chaturvedi; J B Sharma
Journal:  Endocrine       Date:  2018-09-29       Impact factor: 3.633

Review 4.  Neuroendocrine causes of amenorrhea--an update.

Authors:  Lindsay T Fourman; Pouneh K Fazeli
Journal:  J Clin Endocrinol Metab       Date:  2015-01-12       Impact factor: 5.958

Review 5.  Diagnosis and management of hyperprolactinemia.

Authors:  Omar Serri; Constance L Chik; Ehud Ur; Shereen Ezzat
Journal:  CMAJ       Date:  2003-09-16       Impact factor: 8.262

Review 6.  Prolactin Biology and Laboratory Measurement: An Update on Physiology and Current Analytical Issues.

Authors:  Mohamed Saleem; Helen Martin; Penelope Coates
Journal:  Clin Biochem Rev       Date:  2018-02

7.  Identification of IgG-immunocomplex macroprolactin with an immunometric "sandwich" system: technical and clinical considerations.

Authors:  P Amadori; C Dilberis; A Marcolla; M Pinamonti; P Menapace; A Valentini
Journal:  J Endocrinol Invest       Date:  2004-12       Impact factor: 4.256

8.  Macroprolactinemia: predictability on clinical basis and detection by PEG precipitation with two different immunometric methods.

Authors:  P Amadori; C Dilberis; A Marcolla; M Pinamonti; P Menapace; F Dal Bosco
Journal:  J Endocrinol Invest       Date:  2003-02       Impact factor: 4.256

9.  Diagnosis and management of hyperprolactinemia: results of a Brazilian multicenter study with 1234 patients.

Authors:  L Vilar; M C Freitas; L A Naves; L A Casulari; M Azevedo; R Montenegro; A I Barros; M Faria; G C Nascimento; J G Lima; L H Nóbrega; T P Cruz; A Mota; A Ramos; A Violante; A Lamounier Filho; M R Gadelha; M A Czepielewski; A Glezer; M D Bronstein
Journal:  J Endocrinol Invest       Date:  2008-05       Impact factor: 4.256

10.  Hyperprolactinemia in asymptomatic patients is related to high molecular weight posttranslational variants or glycosylated forms.

Authors:  M Guitelman; M E Colombani-Vidal; C C Zylbersztein; L Fiszlejder; M Zeller; O Levalle; H E Scaglia
Journal:  Pituitary       Date:  2002       Impact factor: 4.107

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.